Pacira Pharmaceuticals Inc (PCRX) Stock Rating Reaffirmed by Leerink Swann

Pacira Pharmaceuticals Inc (NASDAQ:PCRX)‘s stock had its “market perform” rating reissued by stock analysts at Leerink Swann in a note issued to investors on Monday.

A number of other research firms have also issued reports on PCRX. BMO Capital Markets reissued a “hold” rating and issued a $45.00 target price on shares of Pacira Pharmaceuticals in a report on Thursday, March 2nd. Wedbush reaffirmed an “outperform” rating and set a $89.00 price objective on shares of Pacira Pharmaceuticals in a report on Thursday, March 2nd. Janney Montgomery Scott lowered Pacira Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $38.00 price objective on the stock. in a report on Thursday, March 2nd. HC Wainwright upped their price objective on Pacira Pharmaceuticals from $48.00 to $59.00 and gave the stock a “buy” rating in a report on Thursday, March 2nd. Finally, Jefferies Group LLC set a $60.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 2nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $54.80.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 2.64% on Monday, reaching $48.65. The company’s stock had a trading volume of 586,765 shares. The company has a 50 day moving average of $44.35 and a 200 day moving average of $37.71. The stock’s market capitalization is $1.83 billion. Pacira Pharmaceuticals has a 1-year low of $29.95 and a 1-year high of $65.64.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, March 1st. The company reported $0.09 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.08. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $73.08 million. Pacira Pharmaceuticals had a negative return on equity of 1.52% and a negative net margin of 13.37%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 earnings per share. Equities research analysts expect that Pacira Pharmaceuticals will post $0.29 earnings per share for the current fiscal year.

Your IP Address:

In other Pacira Pharmaceuticals news, President James S. Scibetta sold 20,000 shares of the business’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $38.53, for a total transaction of $770,600.00. Following the sale, the president now directly owns 29,457 shares in the company, valued at $1,134,978.21. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO David M. Stack sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $38.41, for a total value of $576,150.00. The disclosure for this sale can be found here. 6.90% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of the company. Acrospire Investment Management LLC increased its stake in Pacira Pharmaceuticals by 2,000.0% in the third quarter. Acrospire Investment Management LLC now owns 4,200 shares of the company’s stock worth $144,000 after buying an additional 4,000 shares during the last quarter. Denver Investment Advisors LLC purchased a new stake in Pacira Pharmaceuticals during the fourth quarter worth approximately $214,000. Fisher Asset Management LLC increased its stake in Pacira Pharmaceuticals by 1.4% in the third quarter. Fisher Asset Management LLC now owns 6,282 shares of the company’s stock worth $215,000 after buying an additional 85 shares during the last quarter. Numeric Investors LLC purchased a new stake in Pacira Pharmaceuticals during the fourth quarter worth approximately $239,000. Finally, Rothschild Asset Management Inc. increased its stake in Pacira Pharmaceuticals by 2.5% in the third quarter. Rothschild Asset Management Inc. now owns 7,137 shares of the company’s stock worth $244,000 after buying an additional 175 shares during the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

5 Day Chart for NASDAQ:PCRX

Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit